Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 3, 2006, Pages 245-251

  Choong, Nicholas W ^a   Mauer, Ann M ^a,b   Hoffman, Philip C ^a,b   Rudin, Charles M ^c   Winegarden, Jerome D ^d   Villano, J Lee ^a   Kozloff, Mark ^e   Wade III, James L ^f   Sciortino, David F ^g   Szeto, Livia ^a   Vokes, Everett E ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b University of Chicago   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Ann Arbor Hematology Oncology Associates   (United States)

^e Ingalls Memorial Hospital   (United States)

^f Decatur Memorial Hospital   (United States)

^g Fort Wayne Oncology Hematology   (United States)

Author keywords

Irinotecan; Metastasis; Non small cell lung cancer; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEATH; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPONATREMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; BRAIN TUMOR; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 33847411794     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(15)31575-6     Document Type: Article

References (42)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2006;55:10-30.
2. Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu TE, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-132.
6. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988;6:1474-1480.
7. Newman SJ, Hansen HH. Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 1974;33:492-496.
8. Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
9. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-3736.
10. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-266.
11. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-2771.
12. Combs SE, Gutwein S, Schulz-Ertner D, et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme: phase I/II study. Strahlenther Onkol 2006;181:372-377.
13. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53:259-265.
14. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12:249-254.
15. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2006;61:185-191.
16. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-3650.
17. Adonizio CS, Babb JS, Maiale C, et al. Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer 2002;3:254-258.
18. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-341.
19. Bobola MS, Tseng SH, Blank A, et al. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 1996;2:735-741.
20. Bobola MS, Berger MS, Ellenbogen RG, et al. O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. Clin Cancer Res 2001;7:613-619.
21. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-2399.
22. Lee SM, Thatcher N, Crowther D, Margison GP. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69:452-456.
23. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-4367.
24. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40:484-488.
25. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-1011.
26. Wurm R, Roeschel L, Scheffler D, et al. Phase I-II study with continuous dose-escalated 21 day schedule temozolomide in recurrent high-grade glioma (Abstract 634). Proc Am Soc Clin Oncol 2000;(Abstract 634):164a.
27. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-5947.
28. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2006;352:476-487.
29. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
30. Fukuda M, Oka M, Soda H, et al. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol 2004;54:573-577.
31. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-341.
32. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004;91:482-488.
33. Kakolyris S, Kouroussis C, Souglakos J, et al. Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer. Lung Cancer 2001; 34 (Suppl 4);S71-S76.
34. Coggins CA, Elion GB, Houghton PJ, et al. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 1998;41:485-490.
35. Patel VJ, Elion GB, Houghton PJ, et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res 2000;6:4154-4157.
36. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-4118.
37. Pourquier P, Waltman JL, Urasaki Y, et al. Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 2001;61:53-58.
38. Jones SF, Gian VG, Greco FA, et al. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors. Oncology (Williston Park) 2003;17 (Suppl 5):41-45.
39. Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 2004;27:33-38.
40. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan: a North American Brain Tumor Consortium preliminary report. Oncology (Williston Park) 2002;16 (Suppl 7):33-40.
41. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-616.
42. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2006;352:987-996.